1. Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. (3rd March 2016) Authors: Usmani, S. Z.; Cavenagh, J. D.; Belch, A. R.; Hulin, C.; Basu, S.; White, D.; Nooka, A.; Ervin-Haynes, A.; Yiu, W.; Nagarwala, Y.; Berger, A.; Pelligra, C. G.; Guo, S.; Binder, G.; Gibson, C. J.; Facon, T. Journal: Journal of medical economics Issue: Volume 19:Number 3(2016) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗